Biochemical Recurrence: A Valuable Endpoint?

Part of the Medical Radiology book series (MEDRAD)


Clinically relevant outcomes such as distant metastases and death from prostate cancer do not occur for many years after definitive treatment for localized prostate cancer. In view of the long natural history of prostate cancer, the identification and validation of surrogate endpoints that can be measured earlier and correlate with clinical progression or survival are of great utility in clinical cancer research. With the introduction of prostate-specific antigen (PSA) as a marker in the mid-1980s, PSA has become an important tool for monitoring disease progression following definitve treatment of localized prostate cancer and the concept of “biochemical” recurrence, an event that precedes clinical recurrence by many years, has been developed. Biochemical failure has become widely accepted to evaluate the effectiveness of definitive local therapies and is used for both research and clinical purposes. Biochemical recurrence has been investigated as a prognostic factor and as a potential surrogate endpoint in different stages of disease; however, on the basis of conflicting results from previous studies, a consensus on the ability of biochemical failure to act as a reliable surrogate endpoint for clinical progression and survival has not yet been reached.


Radical Prostatectomy Localize Prostate Cancer Biochemical Recurrence Biochemical Failure Androgen Suppression 


  1. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041Google Scholar
  2. Amling CL, Bergstralh EJ, Blute ML et al (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165:1146–1151PubMedCrossRefGoogle Scholar
  3. Arcangeli G, Saracino B, Gomellini S et al (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78:11–18PubMedCrossRefGoogle Scholar
  4. Arcangeli S, Strigari L, Gomellini S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172–1178PubMedCrossRefGoogle Scholar
  5. Benchikh El Fegoun A, Villers A et al (2008) PSA and follow-up after treatment of prostate cancer. Prog Urol 18:137–144PubMedCrossRefGoogle Scholar
  6. Bolla M, van Poppel H, Collette L et al (2005) European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578PubMedCrossRefGoogle Scholar
  7. Collette L (2008) Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 53:6–9PubMedCrossRefGoogle Scholar
  8. Collette L, Burzykowski T, Caroll KJ et al (2005) PSA is not a valid surrogate endpoint for overall survival in patients with metastatic prostate cancer. A joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum and AstraZeneca Pharmaceuticals. J Clin Oncol 23:6139–6148PubMedCrossRefGoogle Scholar
  9. Collette L, Burzykowski T, Schröder FH (2006) Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 42:1344–1350PubMedCrossRefGoogle Scholar
  10. Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540–545PubMedCrossRefGoogle Scholar
  11. D’Amico AV, Chen M, Renshaw AA et al (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295PubMedGoogle Scholar
  12. D’Amico AV, Chen M-H, de Castro M et al (2012) Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 13:189–195PubMedCrossRefGoogle Scholar
  13. D’Amico AV, Moul JW, Carroll PR et al (2003) Surrogate end point for prostate cancer specific mortality after radical prostatectomy or radiation therapy. J Natl Canc Inst 95:1376–1383CrossRefGoogle Scholar
  14. Denham JW, Steigler A, Wilcox C et al (2008) Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 9:1058–1068PubMedCrossRefGoogle Scholar
  15. Denham JW, Steigler A, Wilcox C et al (2009) Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115:4477–4487PubMedCrossRefGoogle Scholar
  16. Freedland SJ, Sutter ME, Dorey F et al (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61:365–369PubMedCrossRefGoogle Scholar
  17. Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high-risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29PubMedCrossRefGoogle Scholar
  18. Horwitz EM, Thames HD, Kuban DA et al (2005) Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173:797–802PubMedCrossRefGoogle Scholar
  19. Johnson JR, Williams G, Pazdur R (2003) Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1401–1411Google Scholar
  20. Kuban D, Thames H, Levy L et al (2005) Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 61:409–414PubMedCrossRefGoogle Scholar
  21. Kuban DA, Levy LB, Cheung MR et al (2011) Long-term failure patterns and survival in a randomized dose escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79:1310–1317PubMedCrossRefGoogle Scholar
  22. Kuban DA, Nogueras-Gonzalez NG, Hamblin L et al (2010) Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 78(suppl):S58CrossRefGoogle Scholar
  23. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74PubMedCrossRefGoogle Scholar
  24. Kupelian PA, Buchsbaum JC, Patel C et al (2002) Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52:704–711PubMedCrossRefGoogle Scholar
  25. Kwan W, Pickles T, Duncan G et al (2004) PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 60:1040–1046PubMedCrossRefGoogle Scholar
  26. Lamb DS, Denham JW, Joseph D et al (2011) A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the Trog96.01 randomized trial. Int J Radiat Oncol Biol Phys 79:385–391PubMedCrossRefGoogle Scholar
  27. Newling D, Carroll K, Morris T (2004) Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer? J Clin Oncol 22:4652CrossRefGoogle Scholar
  28. Nielsen ME, Partin AW (2007) The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol 9:57–62PubMedCentralPubMedGoogle Scholar
  29. Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996PubMedCrossRefGoogle Scholar
  30. Pollack A, Hanlon AL, Movsas B et al (2003) Biochemical failure as a determinant of distant metastasis and death in prostate cancertreated with radiotherapy. Int J Radiat Oncol Biol Phys 57:19–23PubMedCrossRefGoogle Scholar
  31. Pollack AW, Buyyounouski M, Horwitz E et al (2011) Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 81(suppl):S1CrossRefGoogle Scholar
  32. Prentice RL (1989) Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med 8:431–440PubMedCrossRefGoogle Scholar
  33. Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRefGoogle Scholar
  34. Sandler HM, Dunn RL, McLaughlin PW et al (2000) Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48:629–633PubMedCrossRefGoogle Scholar
  35. Sandler HM, Pajak TF, Hanks GE et al (2003) Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92–02. J Clin Oncol 22:381CrossRefGoogle Scholar
  36. Sathya JR, Davis IR, Julian JA et al (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23:1192–1199PubMedCrossRefGoogle Scholar
  37. Soto DE, Andridge RR, Pan CC et al (2008) In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval. Int J Radiat Oncol Biol Phys 71:1295–1301PubMedCrossRefGoogle Scholar
  38. Stephenson AJ, Bolla M, Briganti A et al (2012) Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 61:443–451PubMedCrossRefGoogle Scholar
  39. Stephenson AJ, Kattan MW, Eastham JA et al (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978PubMedCrossRefGoogle Scholar
  40. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962PubMedCentralPubMedCrossRefGoogle Scholar
  41. Valicenti RK, DeSilvio M, Hanks GE et al (2006) Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys 66:1064–1071PubMedCrossRefGoogle Scholar
  42. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRefGoogle Scholar
  43. Williams SG, Duchesne GM, Millar JL et al (2004) Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1082–1087PubMedCrossRefGoogle Scholar
  44. Zelefsky MJ, Lyass O, Fuks Z et al (1998) Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16:3380–3385PubMedGoogle Scholar
  45. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28:1106–1111PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Therapeutic Radiology and OncologyMedical University of GrazGrazAustria

Personalised recommendations